Allergan Inc. (AGN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.3%. By the end of trading, Allergan rose $2.34 (2.1%) to $114.60 on average volume. Throughout the day, 2,257,838 shares of Allergan exchanged hands as compared to its average daily volume of 2,289,100 shares. The stock ranged in a price between $113.61-$115.84 after having opened the day at $113.69 as compared to the previous trading day's close of $112.26. Other companies within the Health Care sector that increased today were: Enzo Biochem ( ENZ), up 17.4%, Ohr Pharmaceutical ( OHRP), up 11.6%, Cumberland Pharmaceuticals ( CPIX), up 11.1% and Cambrex Corporation ( CBM), up 10.4%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $34.1 billion and is part of the drugs industry. The company has a P/E ratio of 27.1, above the S&P 500 P/E ratio of 17.7. Shares are up 1.1% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Allergan a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, SunLink Health Systems ( SSY), down 10.7%, KaloBios Pharmaceuticals ( KBIO), down 10.0%, Oramed Pharmaceuticals ( ORMP), down 9.5% and Vision-Sciences Inc (DE ( VSCI), down 9.3% , were all laggards within the health care sector with Boston Scientific ( BSX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)